These Roadshows have been sponsored by Novartis Pharmaceuticals UK Ltd. The sponsor has had no control over the educational content of these activities.

Background:

Education is not simply about acquiring facts, but the process of facilitating learning, or the acquisition of knowledge, skills, values, beliefs and habits. When education is about changing practice it is best done with colleagues in an environment that encourages collaboration, reinforcement and self-reflection. The MS Academy Roadshows aim to create just such an environment. This series focuses on more advanced or progressive MS, which up until now has been a neglected area of research and clinical practice. With the imminent arrival of effective DMTs for progressive MS we need to re-evaluate our knowledge and clinical practice around progressive MS and look at the impact the introduction of treatments for progressive MS will have for our practice.

 

LONDON: Finding and diagnosing our patients with progressive MS

Date: 3 July 2019
Time: Registration at 17:45
Venue: 30 Euston Square · Princes Gate Heritage Room · London NW1 2FB

Chair: Dr Robert Brenner, Consultant Neurologist, Royal Free Hospital

The primary objective of this roadshow is to define what we mean when we say progressive MS, how to use MRI to help us predict who will develop progressive MS and to only focus on lower limb function. Another issue that will be addressed are the implications the provision of therapies for progressive MS will have for MS services and how we can locate and make sure all our patients with progressive MS are identified and offered therapies.

Please click on the button below to view the programme and register.

London


LIVERPOOL: Progressive MS is it a different disease?

Date: 13 June 2019
Time: Registration at 17:45
Venue: Crowne Plaza · 2 St Nicholas Pl · Princes Dock · Liverpool L3 1QW

Chair: Dr Anu Jacob, Consultant Neurologist, The Walton Centre

The primary objective of this roadshow is to address whether MS in one, two or three diseases and whether or not lessons can be learnt from other inflammatory diseases of the central nervous system, in particular, NMO spectrum disorder. Why does MS cause progressive disability and NMO not? Or have we missed progressive NMO? Another issue that has to be addressed is as we move into the era of DMTs for progressive MS is the implications this will have for MS services. Will the NHS be able to cope, if and when, DMTs become available for progressive MS?

Please click on the button below to view the programme and register.

Liverpool


GLASGOW: How easy is it to identify progressive MS?

Date: 20 June 2019
Time: Registration at 17:45
Venue: Jurys Inn Glasgow · 80 Jamaica St · Glasgow G1 4QG

Chair: Dr Pushkar Shah, Consultant Neurologist, NHS Greater Glasgow and Clyde

The primary objective of this roadshow is to address the issue of defining and identifying progressive MS in a timely manner and how to use biomarkers to assist in this process. Another issue that will be addressed are the implications the provision of therapies for progressive MS will have for MS services, particularly remote MS services, in rural areas and the Scottish Isles.

Please click on the button below to view the programme and register.

Glasgow


EXETER: What does the pathology of progressive MS tell us about its pathogenesis?

Date: 18 June 2019
Time: Registration at 17:45
Venue: Jurys Inn Exeter Hotel · Western Way · Exeter EX1 2DB

Chair: Prof Nicholas Gutowski, Consultant Neurologist, Royal Devon and Exeter NHS Foundation Trust

The primary objective of this roadshow is to define what we mean when we say progressive MS from a clinical and pathological perspective. Is progressive MS different to relapsing MS? Other issues that will be addressed are lifestyle factors and comorbidities and the holistic management of progressive MS.

Exeter


These Roadshows have been sponsored by Novartis Pharmaceuticals UK Ltd. The sponsor has had no control over the educational content of these activities.